Histopathology of BRCA1- and BRCA2-associated breast cancer

被引:62
作者
Honrado, Emiliano
Benitez, Javier
Palacios, Jose
机构
[1] Ctr Nacl Invest Oncol, Breast & Gynaecol Canc Grp, E-28029 Madrid, Spain
[2] Ctr Nacl Invest Oncol, Dept Human Genet, E-28029 Madrid, Spain
关键词
hereditary breast cancer; BRCA1; BRCA2; molecular pathology; histopathology; immunohistochemistry;
D O I
10.1016/j.critrevonc.2006.01.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hereditary breast carcinomas that are attributable to BRCA1/2 mutations have their own morphological and immunohistochemical characteristics. BRCA1-associated carcinomas are poorly differentiated infiltrating ductal carcinomas that frequently show morphological features of typical or atypical medullary carcinoma. BRCA2-associated breast carcinomas tend to be of higher grade than sporadic age-matched controls. BRCA1 tumors have been found to be more frequently estrogen receptor- and progesterone receptor-negative, and p53-positive than are age-matched controls, whereas these differences are not usually found in BRCA2-associated tumors. In addition, BRCA1- and BRCA2-associated breast carcinomas show a low frequency of HER2 expression. Most BRCA1 breast carcinomas are characterized by the expression of basal (myoepithelial) markers, such as cytokeratin 5/6 and or P-cadherin. These features could be used to distinguish patients who are likely to carry a BRCA1 or BRCA2 germline mutation, thus indicating which gene should be screened for first in families with a high incidence of breast and ovarian cancer. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:27 / 39
页数:13
相关论文
共 124 条
[1]   ERBB2, TBX2, RPS6KB1, and MYC alternations in breast tissues of BRCA1 and BRCA2 mutation carriers [J].
Adem, C ;
Soderberg, CL ;
Hafner, K ;
Reynolds, C ;
Slezak, JM ;
Sinclair, CS ;
Sellers, TA ;
Schaid, DJ ;
Couch, F ;
Hartmann, LC ;
Jenkins, RB .
GENES CHROMOSOMES & CANCER, 2004, 41 (01) :1-11
[2]   Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers [J].
Adem, C ;
Reynolds, C ;
Soderberg, CL ;
Slezak, JM ;
McDonnell, SK ;
Sebo, TJ ;
Schaid, DJ ;
Myers, JL ;
Sellers, TA ;
Hartmann, LC ;
Jenkins, RB .
CANCER, 2003, 97 (01) :1-11
[3]   Inherited BRCA2 mutation associated with high grade breast cancer [J].
Agnarsson, BA ;
Jonasson, JG ;
Björnsdottir, IB ;
Barkardottir, RB ;
Egilsson, V ;
Sigurdsson, H .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 47 (02) :121-127
[4]  
Alvarez S, 2005, CLIN CANCER RES, V11, P1146
[5]  
Armes JE, 1998, CANCER-AM CANCER SOC, V83, P2335, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO
[6]  
2-N
[7]  
Armes JE, 1999, CANCER RES, V59, P2011
[8]   Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer [J].
Arnes, JB ;
Brunet, JS ;
Stefansson, I ;
Bégin, LR ;
Wong, N ;
Chappuis, PO ;
Akslen, LA ;
Foulkes, WD .
CLINICAL CANCER RESEARCH, 2005, 11 (11) :4003-4011
[9]   Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer [J].
Baekelandt, M ;
Holm, R ;
Nesland, JM ;
Tropé, CG ;
Kristensen, GB .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) :3775-3781
[10]  
Brodie S G, 2001, Trends Genet, V17, pS18, DOI 10.1016/S0168-9525(01)02451-9